Teva Pharmaceutical Industries Ltd. $TEVA Stock Holdings Lessened by Beck Mack & Oliver LLC

Key Points

• Beck Mack & Oliver LLC reduced its stake in Teva Pharmaceutical Industries by 2.2%, owning 1,170,735 shares valued at approximately $18 million after selling 26,755 shares in the first quarter.
• Teva has seen several upgrades from analysts, with a consensus average rating of "Buy" and a target price of $24.71, indicating positive market sentiment towards the stock.
• In its recent earnings report, Teva reported $0.66 earnings per share, beating estimates, but with revenue of $4.18 billion, which fell short of the expected $4.34 billion.

Beck Mack & Oliver LLC cut its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 2.2% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,170,735 shares of the company's stock after selling 26,755 shares during the quarter. Beck Mack & Oliver LLC owned about 0.10% of Teva Pharmaceutical Industries worth $17,994,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of TEVA. US Bancorp DE grew its stake in shares of Teva Pharmaceutical Industries by 6.5% in the 1st quarter. US Bancorp DE now owns 10,812 shares of the company's stock worth $166,000 after purchasing an additional 656 shares during the last quarter. Bfsg LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 7.8% during the first quarter. Bfsg LLC now owns 10,960 shares of the company's stock worth $168,000 after purchasing an additional 790 shares during the period. Factorial Partners LLC lifted its stake in Teva Pharmaceutical Industries by 0.3% in the first quarter. Factorial Partners LLC now owns 333,000 shares of the company's stock valued at $5,118,000 after acquiring an additional 1,000 shares during the last quarter. Yousif Capital Management LLC lifted its stake in Teva Pharmaceutical Industries by 1.9% in the first quarter. Yousif Capital Management LLC now owns 55,986 shares of the company's stock valued at $861,000 after acquiring an additional 1,033 shares during the last quarter. Finally, Mackenzie Financial Corp raised its position in shares of Teva Pharmaceutical Industries by 4.1% in the fourth quarter. Mackenzie Financial Corp now owns 29,889 shares of the company's stock valued at $659,000 after purchasing an additional 1,171 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on TEVA shares. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. The Goldman Sachs Group initiated coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 target price on the stock. UBS Group decreased their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Bank of America raised their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Finally, JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and increased their price target for the company from $21.00 to $23.00 in a research report on Monday, May 12th. Two research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company's stock. According to data from MarketBeat, Teva Pharmaceutical Industries has an average rating of "Buy" and an average target price of $24.71.

Teva Pharmaceutical Industries Stock Up 2.0%

Shares of NYSE TEVA opened at $18.41 on Friday. The company has a market cap of $21.11 billion, a price-to-earnings ratio of -115.04, a PEG ratio of 1.09 and a beta of 0.62. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45. The stock has a 50-day moving average price of $16.86 and a two-hundred day moving average price of $16.32. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business had revenue of $4.18 billion during the quarter, compared to the consensus estimate of $4.34 billion. During the same quarter in the prior year, the firm posted $0.61 EPS. The company's revenue for the quarter was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the transaction, the executive vice president owned 9,989 shares in the company, valued at $170,012.78. This trade represents a 38.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric A. Hughes sold 52,742 shares of the firm's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. In the last 90 days, insiders sold 65,001 shares of company stock worth $996,958. 0.49% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.